These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
418 related articles for article (PubMed ID: 24756794)
1. Cabozantinib: a MET, RET, and VEGFR2 tyrosine kinase inhibitor. Grüllich C Recent Results Cancer Res; 2014; 201():207-14. PubMed ID: 24756794 [TBL] [Abstract][Full Text] [Related]
2. Cabozantinib: Multi-kinase Inhibitor of MET, AXL, RET, and VEGFR2. Grüllich C Recent Results Cancer Res; 2018; 211():67-75. PubMed ID: 30069760 [TBL] [Abstract][Full Text] [Related]
3. In vitro and in vivo activity of cabozantinib (XL184), an inhibitor of RET, MET, and VEGFR2, in a model of medullary thyroid cancer. Bentzien F; Zuzow M; Heald N; Gibson A; Shi Y; Goon L; Yu P; Engst S; Zhang W; Huang D; Zhao L; Vysotskaia V; Chu F; Bautista R; Cancilla B; Lamb P; Joly AH; Yakes FM Thyroid; 2013 Dec; 23(12):1569-77. PubMed ID: 23705946 [TBL] [Abstract][Full Text] [Related]
4. Cabozantinib for the treatment of progressive metastatic medullary thyroid cancer. Krajewska J; Olczyk T; Jarzab B Expert Rev Clin Pharmacol; 2016; 9(1):69-79. PubMed ID: 26536165 [TBL] [Abstract][Full Text] [Related]
5. Cabozantinib in Thyroid Cancer. Fallahi P; Ferrari SM; Di Bari F; Materazzi G; Benvenga S; Miccoli P; Antonelli A Recent Pat Anticancer Drug Discov; 2015; 10(3):259-69. PubMed ID: 26152149 [TBL] [Abstract][Full Text] [Related]
6. Cabozantinib (XL184), a novel MET and VEGFR2 inhibitor, simultaneously suppresses metastasis, angiogenesis, and tumor growth. Yakes FM; Chen J; Tan J; Yamaguchi K; Shi Y; Yu P; Qian F; Chu F; Bentzien F; Cancilla B; Orf J; You A; Laird AD; Engst S; Lee L; Lesch J; Chou YC; Joly AH Mol Cancer Ther; 2011 Dec; 10(12):2298-308. PubMed ID: 21926191 [TBL] [Abstract][Full Text] [Related]
7. Integrating Murine and Clinical Trials with Cabozantinib to Understand Roles of MET and VEGFR2 as Targets for Growth Inhibition of Prostate Cancer. Varkaris A; Corn PG; Parikh NU; Efstathiou E; Song JH; Lee YC; Aparicio A; Hoang AG; Gaur S; Thorpe L; Maity SN; Bar Eli M; Czerniak BA; Shao Y; Alauddin M; Lin SH; Logothetis CJ; Gallick GE Clin Cancer Res; 2016 Jan; 22(1):107-21. PubMed ID: 26272062 [TBL] [Abstract][Full Text] [Related]
8. [Cabozantinib: Mechanism of action, efficacy and indications]. Cochin V; Gross-Goupil M; Ravaud A; Godbert Y; Le Moulec S Bull Cancer; 2017 May; 104(5):393-401. PubMed ID: 28477875 [TBL] [Abstract][Full Text] [Related]
9. Activity of XL184 (Cabozantinib), an oral tyrosine kinase inhibitor, in patients with medullary thyroid cancer. Kurzrock R; Sherman SI; Ball DW; Forastiere AA; Cohen RB; Mehra R; Pfister DG; Cohen EE; Janisch L; Nauling F; Hong DS; Ng CS; Ye L; Gagel RF; Frye J; Müller T; Ratain MJ; Salgia R J Clin Oncol; 2011 Jul; 29(19):2660-6. PubMed ID: 21606412 [TBL] [Abstract][Full Text] [Related]
10. Correlative analyses of RET and RAS mutations in a phase 3 trial of cabozantinib in patients with progressive, metastatic medullary thyroid cancer. Sherman SI; Clary DO; Elisei R; Schlumberger MJ; Cohen EE; Schöffski P; Wirth LJ; Mangeshkar M; Aftab DT; Brose MS Cancer; 2016 Dec; 122(24):3856-3864. PubMed ID: 27525386 [TBL] [Abstract][Full Text] [Related]
11. ONC201 Shows Potent Anticancer Activity Against Medullary Thyroid Cancer via Transcriptional Inhibition of Bagheri-Yarmand R; Dadu R; Ye L; Shiny Jebaraj Y; Martinez JA; Ma J; Tarapore RS; Allen JE; Sherman SI; Williams MD; Gagel RF Mol Cancer Ther; 2021 Apr; 20(4):665-675. PubMed ID: 33536187 [TBL] [Abstract][Full Text] [Related]
12. A phase 2 and biomarker study of cabozantinib in patients with advanced cholangiocarcinoma. Goyal L; Zheng H; Yurgelun MB; Abrams TA; Allen JN; Cleary JM; Knowles M; Regan E; Reardon A; Khachatryan A; Jain RK; Nardi V; Borger DR; Duda DG; Zhu AX Cancer; 2017 Jun; 123(11):1979-1988. PubMed ID: 28192597 [TBL] [Abstract][Full Text] [Related]
16. Cabozantinib: a review of its use in patients with medullary thyroid cancer. Hoy SM Drugs; 2014 Aug; 74(12):1435-44. PubMed ID: 25056653 [TBL] [Abstract][Full Text] [Related]
17. LIBRETTO-531: a phase III study of selpercatinib in multikinase inhibitor-naïve Wirth LJ; Brose MS; Elisei R; Capdevila J; Hoff AO; Hu MI; Tahara M; Robinson B; Gao M; Xia M; Maeda P; Sherman E Future Oncol; 2022 Sep; 18(28):3143-3150. PubMed ID: 35969032 [TBL] [Abstract][Full Text] [Related]
18. Cabozantinib in genitourinary malignancies. Zhang T; Park SE; Hong C; George DJ Future Oncol; 2017 Apr; 13(8):755-765. PubMed ID: 27842445 [TBL] [Abstract][Full Text] [Related]
19. Cabozantinib for metastatic breast carcinoma: results of a phase II placebo-controlled randomized discontinuation study. Tolaney SM; Nechushtan H; Ron IG; Schöffski P; Awada A; Yasenchak CA; Laird AD; O'Keeffe B; Shapiro GI; Winer EP Breast Cancer Res Treat; 2016 Nov; 160(2):305-312. PubMed ID: 27714541 [TBL] [Abstract][Full Text] [Related]
20. Cabozantinib for the treatment of advanced medullary thyroid cancer. Nagilla M; Brown RL; Cohen EE Adv Ther; 2012 Nov; 29(11):925-34. PubMed ID: 23104465 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]